Patents Assigned to Gilead Sciences, Inc.
  • Therapeutic compounds
    Patent number: 11993583
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: May 28, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, John O. Link, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • Antibodies that target HIV GP120 and methods of use
    Patent number: 11987617
    Abstract: Antibodies that bind to HIV gp120 and neutralize HIV are disclosed. Also disclosed are methods of using such antibodies alone or in combination with other therapeutic agents to treat or prevent HIV infection.
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: May 21, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Mini Balakrishnan, Brian A. Carr, Magdeleine S. Hung, Manu Kanwar, Doug Rehder, Matthew Robert Schenauer, Loredana Serafini, Nathan D. Thomsen
  • LPA receptor antagonists and uses thereof
    Patent number: 11980609
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (TLD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: May 14, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Joshua A. Kaplan, Megan E. Neubig, Kin S. Yang, Anna Zagorska
  • Remdesivir treatment methods
    Patent number: 11975012
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • Diacylglycerol kinase modulating compounds
    Patent number: 11976072
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Julian A. Codelli, Michael Graupe, Juan A. Guerrero, Stephen D. Holmbo, Tetsuya Kobayashi, Yasamin Moazami, Leena B. Patel, Heath A. Weaver, Jie Xu, Suet C. Yeung, QingMing Zhu
  • Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
    Patent number: 11975017
    Abstract: The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents.
    Type: Grant
    Filed: January 27, 2022
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Nate Larson, Robert G. Strickley
  • Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases
    Patent number: 11976071
    Abstract: The present disclosure provides bifunctional compounds of Formula (I), and pharmaceutically acceptable salts, isotopic forms, isolated stereoisomers, or mixtures of stereoisomers thereof, as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.
    Type: Grant
    Filed: August 18, 2022
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Wylie Palmer, Jeffrey Wu, John Lee, Kerem Ozboya, Tim Kane
  • Inhibitors of peptidylarginine deiminases
    Patent number: 11976083
    Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: May 7, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Eda Y. Canales, Weng K. Chang, Laurent P. Debien, Petr Jansa, Jennifer A. Loyer-Drew, Luisruben P. Martinez, Stephane Perreault, Gary B Phillips, Hyung-Jung Pyun, Roland D. Saito, Michael S. Sangi, Adam J. Schrier, Marina E. Shatskikh, James G. Taylor, Jennifer A. Treiberg, Joshua J. Van Veldhuizen
  • Phospholipid compounds and uses thereof
    Patent number: 11963967
    Abstract: Compounds and methods of using said compounds, alone or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: April 20, 2023
    Date of Patent: April 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Scott E. Lazerwith, Jonathan William Medley, Philip A. Morganelli, Thomas P. Stratton, Peiyuan Wang
  • Combination therapy comprising an ACC inhibitor
    Patent number: 11963961
    Abstract: The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: April 23, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Jamie Geier Bates, Adrian S. Ray
  • Combination MCL-1 inhibitors with anti-cancer agents
    Patent number: 11957693
    Abstract: The present disclosure generally relates to methods of treating cancer by administering an MCL-1 inhibitor and an anticancer agent.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: April 16, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • Capsid inhibitors for the treatment of HIV
    Patent number: 11944611
    Abstract: The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: April 2, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Laura Elizabeth Bauer, Anna Chiu, Eric M. Gorman, Andrew Stephen Mulato, Martin Sunkwang Rhee, Charles William Rowe, Scott P. Sellers, Dimitrios Stefanidis, Winston C. Tse, Stephen R. Yant, Dana J. Levine
  • LPA receptor antagonists and uses thereof
    Patent number: 11939318
    Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD).
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: March 26, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Brian P. Bestvater, Joshua A. Kaplan, Barton W. Phillips, Kin S. Yang, Anna Zagorska
  • 1?-cyano nucleoside analogs and uses thereof
    Patent number: 11939347
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: March 26, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Rao V. Kalla, Dmitry Koltun, Richard L. Mackman, Thao D. Perry, Dustin S. Siegel, Scott P. Simonovich
  • Combination MCL-1 inhibitors with anti-body drug conjugates
    Patent number: 11931424
    Abstract: The present disclosure generally relates to methods of treating or preventing cancer by administering an MCL-1 inhibitor and an antibody-drug conjugate, and optionally one or more additional anti-cancer agents. In particular, the MCL-1 inhibitor can be a compound of formula (I), (II) or (III), or compound A. The antibody-drug conjugate can comprises an anti-Trop-2 antibody and an anti-cancer agent (e.g., SN-38). The combination therapy for treating cancer can have synergistic effect.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: March 19, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Thomas F. Kenney, Clinton K. Matson, Chandrasekar Venkataramani
  • Diacylglycerol kinase modulating compounds
    Patent number: 11932634
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: March 19, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, Juan A. Guerrero, Stephen D. Holmbo, Jesse M. Jacobsen, Tetsuya Kobayashi, Leena B. Patel, Heath A. Weaver, Jie Xu, Suet C. Yeung
  • Diacylglyercol kinase modulating compounds
    Patent number: 11926628
    Abstract: The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
    Type: Grant
    Filed: June 21, 2022
    Date of Patent: March 12, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Julian A. Codelli, Michael Graupe, Juan A. Guerrero, Jesse M. Jacobsen, Tetsuya Kobayashi, Jonathan William Medley, Yasamin Moazami, Leena B. Patel, Jie Xu, Suet C. Yeung
  • Compounds and methods for treatment of viral infections
    Patent number: 11926645
    Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts, crystalline forms, pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: March 12, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elaine Bunyan, Byoung-Kwon Chun, Kassibla E. Dempah, Hon C. Hui, Rao V. Kalla, Richard L. Mackman
  • Pharmaceutical package
    Patent number: D1019381
    Type: Grant
    Filed: June 14, 2022
    Date of Patent: March 26, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Benjamin Luke Kozub, Brian Nilstoft, Kevin Nguyen, James Paul Oberhauser, Roman Shumylo, Joseph Anthony Cordova, Jinhui Yun, William Harold Lizor, Jr., Adam Hilborn, Jesse Arnold Fourt, Léo Boris Marzolf, Pratap Uday Ganapathy, Brooke Genelle Thyng, Caricia Catalani, Soizic Porhel, Jose Angel Meza, Steven M. Scally, Mary Cassandra Lodwick
  • Blister pack
    Patent number: D1027663
    Type: Grant
    Filed: December 13, 2021
    Date of Patent: May 21, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Robert Bridges, Joseph Cordova, Gaurav Dabholkar, Alexandra Fideler, Monica Vazirani